Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase 2/3 1Phase 1/2 1

Status

Completed 8Active not recruiting 8Terminated 6Recruiting 5Withdrawn 1Unknown 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Other solid neoplasm 1Gynecologic 1

Conditions

Neoplasm Metastasis 2Vascular Malformations 1Solid Tumor 1Skin Diseases, Vascular 1Ovarian Neoplasms 1Neoplasms 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Arteriovenous Malformations 1

Interventions

pembrolizumab 223Carboplatin 222Specimen Handling 194Cisplatin 192Magnetic Resonance Spectroscopy 165Radiotherapy 153Bevacizumab 143Gemcitabine 136Cyclophosphamide 135Drug Therapy 119Capecitabine 118Paclitaxel 116Oxaliplatin 111Nivolumab 105Biopsy 104venetoclax 103tislelizumab 83Rituximab 83durvalumab 82toripalimab 78Fluorouracil 73Etoposide 72Docetaxel 69Dexamethasone 69sintilimab 67Pemetrexed 67atezolizumab 65Radiosurgery 65Azacitidine 63130-nm albumin-bound paclitaxel 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Alpelisib × Clear all
NCT05564377 2026-05-27

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05983159 2026-05-05

TARGET-VM

Murdoch Childrens Research Institute

Phase 2 Recruiting
50 enrolled

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

NCT05933395 2026-01-20

GERTRUDE

Dartmouth-Hitchcock Medical Center

Phase 2 Recruiting
135 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Tianjin Medical University Second Hospital

Phase 2 Recruiting
300 enrolled
Other solid neoplasm

Solid Tumor

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡